Clinical Study

The Relationship between H. pylori Infection and Osteoporosis in Japan

Table 1

Clinical characteristics .

MaleFemale valueTotal
95 (47.5)*105 (52.5)*200 (100)*

Patient profile
Age (years) 62.8 (±7.7)**63.4 (±9.6)**0.63763.1 (±8.8)**
BMI (kg/m2)23.6 (±2.6)**22.2 (±3.8)**0.00222.9 (±3.4)**
Alcohol consumption
 Nondrinker36 (37.9)*86 (81.9)*<0.001122 (61.0)*
 Drinker59 (62.1)*19 (18.1)*78 (39.0)*
Smoking
 Nonsmoker44 (46.3)*94 (89.5)*<0.001138 (69.0)*
 Smoker51 (53.7)*11 (10.5)*62 (31.0)*

H. pylori infection status
H. pylori infection
 Negative 57 (60.0)*60 (57.1)*0.682117 (58.5)*
 Positive38 (40.0)*45 (42.9)*83 (41.5)*

Comorbidity
Diabetes mellitus (type 2)
 No83 (87.4)*97 (92.4)*0.364180 (90.0)*
 Yes12 (12.6)*8 (7.6)*20 (10.0)*
Hypertension
 No61 (64.2)*81 (77.1)*0.044142 (71.0)*
 Yes34 (35.8)*24 (22.9)*58 (29.0)*

Internal medical therapies
Proton pump inhibitor (PPI)
 Nonuser63 (66.3)*79 (75.2)*0.165142 (71.0)*
 User32 (33.7)*26 (24.8)*58 (29.0)*
Low dose aspirin (LDA)
 Nonuser82 (86.3)*96 (91.4)*0.267178 (89.0)*
 User13 (13.7)*9 (8.6)*22 (11.0)*

Lumber DXA
Bone mineral density (BMD) ( ) 0.96 (±0.14)**0.81 (±0.16)**<0.0010.88 (±0.17)**
Young adult mean (YAM) (%)91.1 (±13.5)**79.3 (±15.6)**<0.00184.9 (±15.7)**

Bone turnover marker
Bone specific ALP (BAP) (U/L)21.4 (±6.0)**23.4 (±6.6)**0.02522.5 (±6.5)**
Collagen type-I cross-linked N-telopeptide (NTX) (nmolBCE/L)13.6 (±4.8)**14.8 (±5.2)**0.11214.2 (±5.0)**

Upper GI findings
Reflux esophagitis (RE)
 No89 (93.7)*102 (97.1)*0.313191 (95.5)*
 Yes6 (6.3)*3 (2.9)*9 (4.5)*
 LA-grade A437
 Grade B202
 Grade C000
 Grade D000
Hiatal hernia
 No47 (49.5)*62 (59.0)*0.175109 (54.5)*
 Yes48 (50.5)*43 (41.0)*91 (45.5)*
Peptic ulcer disease (PUD)
 No83 (87.4)*91 (86.7)*0.883174 (87.0)*
 Yes12 (12.6)*14 (13.3)*26 (13.0)*
 Gastric ulcer51015
 Duodenal ulcer426
 Gastroduodenal ulcer325
Endoscopic gastric mucosal atrophy (EGA)1.9 (±1.8)**1.8 (±2.0)**0.8111.8 (±1.9)**
 C-0283866
 C-1262551
 C-211718
 C-33912
 O-1161127
 O-291019
 O-3257

(%), **median (±SD).